These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART. Arrizabalaga J; Arazo P; Aguirrebengoa K; García-Palomo D; Chocarro A; Labarga P; Muñoz-Sánchez MJ; Echevarría S; Oteo JA; Uriz J; Letona S; Fariñas MC; Peralta G; Pinilla J; Ferrer P; Alvarez ML; Iribarren JA HIV Clin Trials; 2007; 8(5):328-36. PubMed ID: 17956834 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754 [TBL] [Abstract][Full Text] [Related]
14. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204 [TBL] [Abstract][Full Text] [Related]
15. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS; J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763 [TBL] [Abstract][Full Text] [Related]
16. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316 [TBL] [Abstract][Full Text] [Related]
17. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK; N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366 [TBL] [Abstract][Full Text] [Related]
18. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. Moltó J; Ruiz L; Valle M; Martinez-Picado J; Bonjoch A; Bravo I; Negredo E; Heilek-Sneider GM; Clotet B Antivir Ther; 2006; 11(1):47-51. PubMed ID: 16518959 [TBL] [Abstract][Full Text] [Related]
19. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G; J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879 [TBL] [Abstract][Full Text] [Related]
20. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. Havlir DV; Koelsch KK; Strain MC; Margot N; Lu B; Ignacio CC; Miller MD; Wong JK; J Infect Dis; 2005 Apr; 191(7):1164-8. PubMed ID: 15747253 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]